290 related articles for article (PubMed ID: 22887791)
1. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis.
Choi SH; Lee SY; Hwang JY; Lee SH; Yoo KH; Sung KW; Koo HH; Kim YJ
Pediatr Blood Cancer; 2013 Jan; 60(1):82-7. PubMed ID: 22887791
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
3. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.
Brüggemann RJ; Antonius T; Heijst Av; Hoogerbrugge PM; Burger DM; Warris A
Ther Drug Monit; 2008 Dec; 30(6):643-6. PubMed ID: 19057370
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole plasma monitoring.
Pasqualotto AC; Shah M; Wynn R; Denning DW
Arch Dis Child; 2008 Jul; 93(7):578-81. PubMed ID: 18252755
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
11. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
[TBL] [Abstract][Full Text] [Related]
12. Impact of therapeutic drug monitoring of voriconazole in a pediatric population.
Brüggemann RJ; van der Linden JW; Verweij PE; Burger DM; Warris A
Pediatr Infect Dis J; 2011 Jun; 30(6):533-4. PubMed ID: 21127454
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
Trifilio S; Ortiz R; Pennick G; Verma A; Pi J; Stosor V; Zembower T; Mehta J
Bone Marrow Transplant; 2005 Mar; 35(5):509-13. PubMed ID: 15654347
[TBL] [Abstract][Full Text] [Related]
14. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
Trifilio S; Singhal S; Williams S; Frankfurt O; Gordon L; Evens A; Winter J; Tallman M; Pi J; Mehta J
Bone Marrow Transplant; 2007 Sep; 40(5):451-6. PubMed ID: 17589527
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
18. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.
Shima H; Miharu M; Osumi T; Takahashi T; Shimada H
Pediatr Blood Cancer; 2010 Jul; 54(7):1050-2. PubMed ID: 20146339
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
20. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.
Bartelink IH; Wolfs T; Jonker M; de Waal M; Egberts TC; Ververs TT; Boelens JJ; Bierings M
Antimicrob Agents Chemother; 2013 Jan; 57(1):235-40. PubMed ID: 23114771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
